Capmatinib is a kind of kinase inhibitor. It mostly blocks the MET pathway, which plays a role in cancer’s growth. It’s meant to treat metastatic NSCLC, specifically when you have a MET mutation where part 14 is missing.
You can get Capmatinib in two doses, either 150 mg or 200 mg. They’re both pills with a coating. Most people take 400 mg of the medicine two times a day, and it doesn’t matter if you eat before or after taking it.
The pills come in bottles and each bottle has about 60 of ’em.
